Valuation: Repligen Corporation

Market Cap 10.85B 9.64B 9.01B 8.21B 15.46B 1,045B 15.67B 109B 42.2B 532B 40.73B 39.85B 1,709B P/E 2026 *
254x
P/E 2027 * 111x
Enterprise Value 10.58B 9.4B 8.79B 8.01B 15.08B 1,019B 15.29B 106B 41.17B 519B 39.74B 38.88B 1,667B EV / Sales 2026 *
12.8x
EV / Sales 2027 * 10.7x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 week+5.20%
Current month+8.94%
1 month+11.54%
3 months+42.30%
6 months+75.15%
Current year+21.42%
1 week 158.35
Extreme 158.35
173.65
1 month 139.45
Extreme 139.45
173.65
3 years 86.86
Extreme 86.86
194.4
5 years 86.86
Extreme 86.86
264
10 years 24.04
Extreme 24.04
281
Manager TitleAgeSince
Chief Executive Officer 56 01/09/2024
Director of Finance/CFO 52 25/09/2023
Chief Tech/Sci/R&D Officer - 01/08/2025
Director TitleAgeSince
Director/Board Member 60 12/06/2014
Director/Board Member 67 01/10/2015
Director/Board Member 61 01/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
-6.73%+5.08%+50.22%+12.02% 10.85B
-2.17%-6.57%-27.81%-0.17% 171B
+0.17%-3.20%-9.24%+10.31% 110B
-0.88%-0.16%-26.16%-0.11% 106B
-0.69%-3.57%-47.61%-12.45% 75.99B
+3.17%-0.80%-0.88%+72.13% 57.3B
-0.52%-2.44%-4.86%-31.12% 48.76B
+3.44%+7.90%+19.12%+59.15% 50.19B
-0.85%-0.82%-18.96%+18.41% 41.14B
-0.07%-1.71%+28.15%-7.58% 32.56B
Average +0.44%-1.46%-3.80%+12.06% 77B
Weighted average by Cap. +0.10%-2.07%-15.35%+9.06%

Financials

2026 *2027 *
Net sales 827M 735M 687M 626M 1.18B 79.63B 1.19B 8.31B 3.22B 40.55B 3.11B 3.04B 130B 976M 867M 811M 739M 1.39B 93.98B 1.41B 9.81B 3.8B 47.86B 3.66B 3.59B 154B
Net income 41.92M 37.24M 34.82M 31.73M 59.74M 4.04B 60.56M 421M 163M 2.06B 157M 154M 6.6B 98.84M 87.79M 82.1M 74.81M 141M 9.52B 143M 993M 384M 4.85B 371M 363M 15.57B
Net Debt -265M -235M -220M -200M -377M -25.5B -383M -2.66B -1.03B -12.99B -994M -973M -41.72B -438M -389M -364M -332M -624M -42.17B -633M -4.4B -1.7B -21.48B -1.64B -1.61B -68.99B
Logo Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.
Employees
-
Date Price Change
01/10/26 €158.60 -6.73%
30/09/26 €170.05 -0.90%
29/09/26 €171.60 +0.26%
28/09/26 €171.15 +2.76%
25/09/26 €166.55 -0.80%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
192.23USD
Average target price
189.70USD
Spread / Average Target
-1.32%

Quarterly revenue - Rate of surprise